Top

Published in:

01-08-2008 | Melanomas

Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion

Authors: Georgia M. Beasley, MD, Rebecca P. Petersen, MD, MS, Jin Yoo, MD, Nicole McMahon, BS, Thomas Aloia, MD, William Petros, PhD, Gretchen Sanders, BS, BSN, Tsung-Yen Cheng, MD, Scott K. Pruitt, MD, PhD, Hilliard Seigler, MD, Douglas S. Tyler, MD

Published in: Annals of Surgical Oncology | Issue 8/2008

Abstract

Background

Isolated limb infusion (ILI) is a recently described minimally invasive technique developed in Australia for delivering regional chemotherapy. This study examined the efficacy and toxicity of ILI, compared to hyperthermic isolated limb perfusion (HILP), in treating extremity in-transit melanoma.

Methods

Variables from a prospective single institution database of 120 regionally treated melanoma patients (1995–2007) were compared using chi-square analysis. This included 61 consecutive ILI treatments in 58 patients and 59 HILP treatments in 54 patients. Response was defined at 3 months using the response evaluation criteria in solid tumors (RECIST). ILI was performed using melphalan (LPAM) and dactinomycin for 30 min after limb temperature reached 37°C. HILP was performed using LPAM for 60 min after limb temperature reached 38.5°C.

Results

For ILI (n = 61), the complete response (CR) rate was 30%, the partial response (PR) rate was 14%, and there was no response (NR) in 56% of patients. The median duration of CR was 12 months and 18% of patients experienced (grade ≥3) toxicity. HILP (n = 59) was associated with a better (P < 0.001) response rate (CR 57%, PR 31%, and NR 12%) however, more patients (32%) experienced grade ≥3 toxicity (P = 0.037). The dose of LPAM was corrected for ideal body weight (IBW) in 40 out of 61 ILI procedures, and 13 of 59 HILP procedures. This dosing modification was associated with decreased toxicity (P = 0.024) without diminishing response.

Conclusion

ILI was found to be a well-tolerated alternative to HILP. While ILI does not appear to be as effective as HILP, it does seem to be associated with less morbidity.

Balch CM, Houghton AN, Peters LJ. (1993) Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th edition. JB Lippincott, Philadelphia. p. 1612

Pawlik TW, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2004; 11:1612—61CrossRef

Minor DR, Allen RE, Alberts D, et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985; 55:2638–44PubMedCrossRef

Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic aniblastic perfusion. Cancer 1989; 63:2551–61PubMedCrossRef

Klaase JM, Kroon BBR, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115:39–45PubMed

Kroon BR, van Geel AN, Benckhuijsen C, et al. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res 1987; 7:4411–2

Fraker DL, Alexader HR, Ross M, et al. A phase III trial of isolated limb infusion perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF-α) plus interferon-gamma (IFN). Ann Surg Oncol 2002; 9:S8CrossRef

Skene AL, Bulman AS, Williams TF, et al. Hyperthermic isolated limb perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990; 77:765–7PubMedCrossRef

Fraker DL, Eggermont AMM. (2003) Hyperthermic regional perfusion for melanoma of the limbs. In: Balch H, Sober S, eds. Cutaneous Melanoma, 14th edition. Quality Medical, St. Louis, MO

10.

Sanki A, Kam PCA, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma. Ann Surg 2007; 245:591–6PubMedCrossRef

11.

Thompson JF, Kam PC, Waugh RC, et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238–47PubMedCrossRef

12.

Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Regional Cancer Treat 1994;7:188–92

13.

Lindner P, Doubrovsky A, Kam PCA, et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127–36PubMed

14.

Cornett WR, McCall LM, Petersen RP, et al. Prospective randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone versus melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24:4196–201PubMedCrossRef

15.

Brady MS, Brown K, Patel A, et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006;13:1123–9PubMedCrossRef

16.

Aloia TA, Grubbs E, Onaitis M, et al. Predictors of outcome after hyperthermic limb perfusion: role of tumor response. Arch Surg 2005; 140:1115–20PubMedCrossRef

17.

Ehrsson H, Eksborg S, Lindfors A. Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine. J Chromatogr Biomed Appl 1986; 380:220

18.

Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–48PubMed

19.

Cheng T-Y, Grubbs E, Abdul-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg 2003; 186:460–7PubMedCrossRef

20.

Zager JS, Gershenwald JE, Aldrink J, et al. Isolated limb infusion for locally recurrent and in-transit extremity melanoma: combined institutional initial experience. Presented at Society of Surgical Oncology 59th annual cancer symposium. San Diego, CA March 23–26, 2006

21.

Brady MS, Patel A, Brown K, et al. Isolated limb infusion for patients with advanced extremity melanoma and soft tissue sarcoma. Final report of a Phase II trial. Presented at Society of Surgical Oncology 60th annual cancer symposium. Washington, DC March 15–18, 2007

22.

Siemann DW, Chapman M, Beikrich A. Effects of oxygenation and pH on tumor cell response to aklylating chemotherapy. Int J Radiat Oncol Biol Phys 1991; 20:287–9PubMed

23.

Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremity. Surg Gynecol Obstet 1969; 129:305PubMed

24.

25.

Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985; 15:32–5CrossRef

26.

Minor DR, Allen RE, Alberts D, et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985; 55:2638–44PubMedCrossRef

27.

Kroon BB. Regional isolated perfusion in melanoma of the limbs: accomplishments, unsolved problems, future. Eur J Surg Oncol 1998;14:101–10

28.

Abdel-Wahab OI, Grubbs E, Viglianti B. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Can Res 2004;10:5919–29CrossRef

29.

Hildebrandt B, Wust P, Ahlers O. The cellular and molecular basis of hyperthermia. Crit Rev Oncol/Hematol 2002; 43:33–56CrossRef

30.

Thompson JF, Hunt JA, Shannon KF, et al. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132:903–7PubMed

31.

Wieberdink J, Benckhuijsen C, Braat RP. Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905–10PubMedCrossRef

Title: Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion
Authors: Georgia M. Beasley, MD
Rebecca P. Petersen, MD, MS
Jin Yoo, MD
Nicole McMahon, BS
Thomas Aloia, MD
William Petros, PhD
Gretchen Sanders, BS, BSN
Tsung-Yen Cheng, MD
Scott K. Pruitt, MD, PhD
Hilliard Seigler, MD
Douglas S. Tyler, MD
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 8/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-008-9988-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2008

The Lymphatic Anatomy of the Breast and Its Implications for Sentinel Lymph Node Biopsy: A Human Cadaver Study

Comparison of Central and Extended Left Pancreatectomy for Lesions of the Pancreatic Neck

Breast Lymphatic Anatomy and Implications for Sentinel Lymph Node Biopsy

Myxoma Virus Is Oncolytic for Human Pancreatic Adenocarcinoma Cells

Clinical Significance of Intraoperative Bile Duct Margin Assessment for Hilar Cholangiocarcinoma

Surgical Management and Prognostic Factors of Hilar Cholangiocarcinoma: Experience with 115 Cases in China